Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

May 4, 2021

Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L’Huillier brings over two...

BGV Announces New Investment with i2020 Accelerator and Orbimed in Neurology-focused Therapeutics

Apr 29, 2021

Naarden, The Netherlands, 22 April 2021. - BioGeneration Ventures (BGV), together with i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, and OrbiMed have announced a new startup investment in Brenig Therapeutics, a...

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders

Apr 6, 2021

Phase 1 clinical study investigates safety and tolerability, pharmacokinetics and pharmacodynamic effects of first-in-class azasugar AZ-3102 in healthy subjects AZ-3102 is being initially developed for the treatment of patients suffering from GM1 and GM2...

How large pharma impacts biotechnology startup success – Nature Biotechnology

Feb 16, 2021

BGV's Daniela Couto and Gina Melcher von Dydiowa together with Sander van Deventer of Forbion published an article in Nature Biotechnology on pharma involvement in biotech startup success. Click on this link to read the whole article. Abstract: Many novel therapeutic...

News overview

Next events

BGV to Attend the 7ᵗʰ Annual Immuno-Oncology Innovation Forum

May 10, 2021

The 7th Annual IOIF takes place from 18-20 May. It will feature more than 14 hours of high-level speeches and panel discussions by leading industry stakeholders. This year, there is a global company showcase of about 25 presentations by established public, private,...

BioEquity 17-19 May 2021

Apr 6, 2021

The BGV team shall attend the Bio-Equity 2021 online conference. Partnering can be scheduled through the online platform. https://conferences.biocentury.com/bioequity-europe-2021

Event overview